MarginsXMarginsX
Home › Markets › Health Care › APUS

Apimeds Pharmaceuticals US Inc. (APUS)

APUS trades on NYSE in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$2.04
-8.52% on the day
Market cap
$3.1M
Nano cap
Revenue
Recent IPO: no annual report filed yet
Net income
Recent IPO: no annual report filed yet

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.

Profile

FieldValue
TickerAPUS on NYSE
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryNot reported by the screener
IPO year2025
SEC CIK0001894525
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials

Recent IPO: no annual report filed yet.

Warning signs

Cash runway
0.3 months
$278K cash at June 30, 2026
Share count, 1 year
+20.0%
2025-08-18 to 2026-08-12
Going-concern doubt
Yes
10-Q filed August 14, 2026
Insider net buying, 12 months
$0
Through September 30, 2026
SignFindingSource
Going concernStates substantial doubt about continuing as a going concern.
"These conditions raise substantial doubt about the Company's ability to continue as a going concern within one year after the date these condensed consolidated financial statements are issued."
10-Q 2026-08-14
Cash and burn$278K cash; operating cash flow -$3.3M a quarter.Report 2026-06-30
Shares outstanding1,509,118 (2026-08-12); 12,575,983 a year earlier. 1y figure adjusted for split (1-for-10 overall).Cover page 2026-08-12
Reverse splits, 3 years1; latest 1-for-10 on 2026-07-24Source 2026-07-24
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 months1 (8-K item 3.01)8-K 2026-04-22
AuditorKreit & Chiu CPA LLP, New York, New York, United StatesPCAOB Form AP 2026-05-08
Late filings, 12 months2 NT noticesNT 10-Q 2026-05-15
Insider trades, 12 monthsBought $0, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q2 2026
2026-06-30
Not filed-$20.2M-$5.7M$278K$18.9MNeeds four quarters10-Q 2026-08-14
Q1 2026
2026-03-31
Not filed-$35.1M-$2.1M$980K$8.9MNeeds four quarters10-Q 2026-08-14
Q4 2025
2025-12-31
Not filed-$1.2M-$3.8M$1.6M$7.1MNeeds four quarters10-K 2026-05-04
Q3 2025
2025-09-30
Not filed-$1.8M-$1.7M$7.0MNo debt tagsNeeds four quarters10-Q 2025-11-12
Q2 2025
2025-06-30
Not filed-$2.7M-$3.4M$8.7MNo debt tagsNeeds four quarters10-Q 2026-08-14
Q1 2025
2025-03-31
Not filed-$402K-$20K$250KNo debt tagsNeeds four quarters10-Q 2026-08-14
Q4 2024
2024-12-31
Not filed-$312K-$100K$3KNo debt tagsNeeds four quarters10-K 2026-05-04
Q3 2024
2024-09-30
Not filed-$333K-$187K$27KNo debt tagsNeeds four quarters10-Q 2025-11-12

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document
PROSPECTUS
424B42025-05-09
Latest annual report
ANNUAL REPORT
10-K2026-05-04
Latest quarterly / interim
QUARTERLY REPORT
10-Q2026-11-16
Latest current report
CURRENT REPORT
8-K2026-10-13

Source: SEC EDGAR submissions feed, 131 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-17.6%
1 month-51.7%
3 months-52.6%
Year to date-86.4%
1 year-92.0%
From 52-week high-94.3%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
RDHLRedhill Biopharma Ltd.$0.3605-3.87%$3.2M
GRIGRI Bio Inc.$1.40-18.60%$3.1M
MDCXMedicus Pharma Ltd. Common Stock$1.69-13.33%$3.2M
MBIOMustang Bio Inc.$0.3947-6.34%$3.0M
NRSNNeuroSense Therapeutics Ltd.$1.56-7.40%$3.0M
DRMADermata Therapeutics Inc.$0.5985-3.65%$3.0M
SILOSilo Pharma Inc.$1.57-14.40%$3.4M
ERNAErnexa Therapeutics Inc.$1.69+0.60%$2.9M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier